Asthma and lower airway diseaseHeterogeneity of severe asthma in childhood: Confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program
Section snippets
Methods
The SARP is an NHLBI-supported research program with recruitment of children 6 to 17 years of age across 5 centers in the United States. Each of the SARP centers is affiliated with a major university teaching program, and children are recruited into SARP from the outpatient clinics and inpatient hospital wards of those academic centers. As a result, children enrolled in SARP are more likely to have difficult asthma and are representative of a referral population of children who receive care at
Results
Results from 273 children (mean age 10 years) enrolled in SARP across 4 centers in Atlanta, Ga, Winston-Salem, NC, Pittsburgh, Pa, St Louis, Mo, and Charlottesville, Va, were available for analysis. Of these, 112 were missing 1 or more of the cluster variables and were excluded. The features of excluded children did not differ from those of the final sample (see this article’s Table E6 in the Online Repository at www.jacionline.org). The final sample included 161 children. Features of the
Discussion
Asthma in children is a complicated and heterogeneous disorder with distinct phenotypes. By using an unsupervised cluster analysis in children with a wide range of asthma severity characterized in the SARP network, we have identified 4 clusters of childhood asthma with shared phenotypic features. Similar to the previous SARP report that described increased allergic sensitization in clusters of adults with early-onset asthma,21., 27. clusters of childhood asthma were all atopic, although the
References (38)
- et al.
Asthma: clinical expression and molecular mechanisms
J Allergy Clin Immunol
(2010) - et al.
Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide
J Allergy Clin Immunol
(2006) - et al.
Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma
J Allergy Clin Immunol
(2007) - et al.
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program
J Allergy Clin Immunol
(2007) - et al.
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation
J Allergy Clin Immunol
(2004) - et al.
Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study
Lancet
(2008) - et al.
The Melbourne Asthma Study: 1964-1999
J Allergy Clin Immunol
(2002) - et al.
Mild to moderate asthma affects lung growth in children and adolescents
J Allergy Clin Immunol
(2006) - et al.
Differences between asthma exacerbations and poor asthma control
Lancet
(1999) - et al.
Ethnic differences in asthma and associated phenotypes: collaborative study on the genetics of asthma
J Allergy Clin Immunol
(2001)
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group
N Engl J Med
Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007
J Allergy Clin Immunol
Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma
Eur Respir J
Costs of asthma are correlated with severity: a 1-yr prospective study
Eur Respir J
Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma
Allergy
Global strategy for asthma management and prevention: GINA executive summary
Eur Respir J
Phenotypic differences between pediatric and adult asthma
Proc Am Thorac Soc
Is forced expiratory volume in one second the best measure of severity in childhood asthma?
Am J Respir Crit Care Med
Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function
Am J Respir Crit Care Med
Cited by (369)
Management of the pediatric patient with asthma and obesity
2024, Annals of Allergy, Asthma and ImmunologyGEMA 5.3. Spanish Guideline on the Management of Asthma
2023, Open Respiratory ArchivesControversies in Allergy: Are Biologic Treatment Responses in Severe Asthma the Same in Adults and Children?
2023, Journal of Allergy and Clinical Immunology: In PracticeMaternal stress increases risk of allergic lung inflammation in adult mice
2023, ImmunobiologyBiologics in the treatment of asthma in children and adolescents
2023, Journal of Allergy and Clinical ImmunologyEosinophilic and noneosinophilic asthma: Beyond severe asthma
2023, Asthma in the 21st Century: New Research Advances
Supported by National Institutes of Health grants RO1 HL069170, RO1 HL069167, RO1 HL069174, RO1 HL69149, and RO1 HL091762 and in part by the Center for Developmental Lung Biology, Children’s Healthcare of Atlanta, and PHS grants UL1 RR025008, KL2 RR025009, TL1 RR025010, and UL1 RR024992 from the Clinical and Translational Science Award Program, National Institutes of Health, National Center for Research Resources.
Disclosure of potential conflict of interest: A. M. Fitzpatrick has received research support from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. W. G. Teague is a speaker for Merck, has received research support from the National Institutes of Health and the American Lung Association, and is a volunteer for Not One More Life. D. A. Meyers has received research support from the National Institutes of Health. S. P. Peters has received research support from the National Institutes of Health, National Heart, Lung, and Blood Institute Severe Asthma Research Program. M. Castro is a consultant for Electrocore, NKTT, Schering, Asthmatx, and Cephalon; is on the advisory board for Genentech; is a speaker for AstraZeneca, Boehringer-Ingelheim, Pfizer, Merck, and GlaxoSmithKline; has received grants from Asthmatx, Amgen, Ception, Genentech, Medimmune, Merck, Novartis, the National Institutes of Health, and GlaxoSmithKline; and has received royalties from Elsevier. L. B. Bacharier has received honoraria from AstraZeneca and has received honoraria from and is on the advisory board for Genentech, Glaxo-SmithKline, Merck, Schering-Plough, and Aerocrine. B. M. Gaston has received research support from the National Institutes of Health and has served as an expert witness on the topic of exhaled nitric oxide for Apieron. E. R. Bleecker is an advisor and consultant for Aerovance, AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Wyeth and has received research support from Aerovance, Amgen, AstraZeneca, Boehringer-Ingelheim, Centocor, Ception, Genentech, GlaxoSmithKline, the National Institutes of Health, Novartis, Pfizer, and Wyeth. The rest of the authors have declared that they have no conflict of interest.
- ∗
A complete listing of Severe Asthma Research Program investigators is provided in the acknowledgments.